Literature DB >> 27265474

Surgical Management of Benign and Borderline Phyllodes Tumors of the Breast.

Amandine Moutte1, Nicolas Chopin1, Christelle Faure1, Frédéric Beurrier1, Christophe Ho Quoc1, Florence Guinaudeau1, Isabelle Treilleux2, Nicolas Carrabin1,3.   

Abstract

Phyllodes tumors (PT) are uncommon fibroepithelial breast neoplasms and there is currently no clear consensual treatment for these tumors. The aim of our study was to evaluate the surgical management and outcome of benign and borderline PT. We retrospectively assessed 76 cases of benign or borderline PT managed at the Leon Berard comprehensive cancer center in Lyon, France between July 2003 and December 2013. The mean age at diagnosis was 37.9 years and the median follow-up was 58 months. Seventy-five patients (99%), with a mean tumor size of 27 mm, underwent a breast-conserving procedure. The tumor margins were considered positive (when the tumor was present at the inked surgical section) in seven of 76 cases (9%) and negative in 65 out of 76 cases (86%). We observed the presence of small negative surgical margins <10 mm in 89% and <1 mm in 71% of the patients. Although no re-excision was performed to increase these margins, we did not see any increase in the local recurrence rate (4%) when compared to recurrence rates reported in the literature. We thus suggest that systematic revision surgery for close or positive surgical margins for benign PT should not be systematically performed. However, as recurrences occur within 2 years of initial excision, we recommend a regular clinical and imaging follow-up especially during this period for which patient's compliance is essential.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  benign phyllode tumor; borderline phyllode tumor; surgical margins

Mesh:

Year:  2016        PMID: 27265474     DOI: 10.1111/tbj.12623

Source DB:  PubMed          Journal:  Breast J        ISSN: 1075-122X            Impact factor:   2.431


  8 in total

1.  Surgical management in phyllodes tumors of the breast: a systematic review and meta-analysis.

Authors:  Yufan Wei; Yanying Yu; Yashuang Ji; Yuting Zhong; Ningning Min; Huayu Hu; Qingyu Guan; Xiru Li
Journal:  Gland Surg       Date:  2022-03

Review 2.  Fibroepithelial tumours of the breast-a review.

Authors:  Melinda F Lerwill; Andrew H S Lee; Puay Hoon Tan
Journal:  Virchows Arch       Date:  2021-09-10       Impact factor: 4.064

3.  Assessment of quantitative dynamic contrast-enhanced MRI in distinguishing different histologic grades of breast phyllode tumor.

Authors:  Zhilong Yi; Mingwei Xie; Guangzi Shi; Ziliang Cheng; Hong Zeng; Ningyi Jiang; Zhuo Wu
Journal:  Eur Radiol       Date:  2021-09-07       Impact factor: 7.034

Review 4.  Width of margins in phyllodes tumors of the breast: the controversy drags on?-a systematic review and meta-analysis.

Authors:  Arnaud Toussaint; Romain Piaget-Rossel; Coraline Stormacq; Patrice Mathevet; Karine Lepigeon; Patrick Taffé
Journal:  Breast Cancer Res Treat       Date:  2020-09-15       Impact factor: 4.872

Review 5.  Fibroepithelial lesions revisited: implications for diagnosis and management.

Authors:  Puay Hoon Tan
Journal:  Mod Pathol       Date:  2020-05-27       Impact factor: 7.842

6.  Coexisting DCIS and phyllodes breast tumors in Young Chinese women: Case series.

Authors:  Luona Sun; Roger Zhu; Paula Ginter; Manmeet Malik; Kap-Jae Sung; J Melissa Hughes; Beth Siegel; Jacqueline Tsai
Journal:  Int J Surg Case Rep       Date:  2019-02-08

7.  Re-excision or "wait and watch"-a prediction model in breast phyllodes tumors after surgery.

Authors:  Xue Chao; Xiaoyan Jin; Cui Tan; Peng Sun; Junwei Cui; Hui Hu; Qian Ouyang; Kai Chen; Wei Wu; Zhanghai He; Yan Nie; Herui Yao
Journal:  Ann Transl Med       Date:  2020-03

8.  Predicting the pathological grade of breast phyllodes tumors: a nomogram based on clinical and magnetic resonance imaging features.

Authors:  Xiaowen Ma; Lijuan Shen; Feixiang Hu; Wei Tang; Yajia Gu; Weijun Peng
Journal:  Br J Radiol       Date:  2021-07-08       Impact factor: 3.629

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.